-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis failed an advanced trial for a muscle disorder disease, and the stock prices of some pharmaceutical company developers fell. SAREPTA THERAPEUTICS fell 11.4% and DYNE THERAPEUTICS fell 22%.

Zhitongcaijing·09/08/2026 13:57:06
Listen to the news
Novartis failed an advanced trial for a muscle disorder disease, and the stock prices of some pharmaceutical company developers fell. SAREPTA THERAPEUTICS fell 11.4% and DYNE THERAPEUTICS fell 22%.